You are here

Article Text

Article menu

This article has a Reply. Please see:

Download PDFPDF

Letter
Bone density loss in Crohn’s disease: role of TNF and potential for prevention by bupropion
Free
  1. R E Kast,
  2. E L Altschuler
  1. Department of Psychiatry, University of Vermont, Vermont, USA
  1. Correspondence to:
    Dr R E Kast
    Department of Psychiatry College of Medicine, University of Vermont, 2 Church St, Burlington, Vermont 05401, USA; rekastemail.com

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We note with interest the demonstration by Card et al that the increased hip fracture rate in Crohn’s disease (CD), and by inference the diminished bone density commonly noted in CD, is only to a minor degree secondary to iatrogenic corticosteroid use (Gut 2004;53;251–5). The subject of bone mineral density loss in CD has been recently reviewed; tumour necrosis factor α (TNF-α) is suspected of being an important mediator of this loss.1,2 Evidence has been published for localised overproduction of TNF-α being largely responsible for the bone loss seen in rheumatoid arthritis,3,4 psoriatic arthritis,5 multiple myeloma,6 hip prosthesis loosening,7 periodontal disease,8 and spondyloarthropathies.9 Anti-TNF-α antibody has been shown to slow the bone loss of spondyloarthropy9 and rheumatoid arthritis.3,10

    We have found that the commonly used antidepressant bupropion can induce remission in CD11,12 and have found that bupropion can lower TNF-α levels.13 If bupropion is found to be effective in CD and to lower TNF-α levels in large trials, it might be considered for use in bone loss and osteoporosis, in CD or otherwise.

    References

    1. ↵
      Lichtenstein GR. Evaluation of bone mineral density in IBD: current safty focus. Am J Gastroenterol2003;98 (suppl 12) :S24–30.
      OpenUrl
    2. ↵
      Nanes MS. TNF-alpha: molecular and cellular mechanisms in skeletal pathology. Gene2003;321:1–15.
      OpenUrlCrossRefPubMedWeb of Science
    3. ↵
      Bingham CO iii. The pathogenesis of rheumatoid arthritis: pivotal cytokines involved in bone degradation and inflammation. J Rheumatol Suppl2002;65:39.
      OpenUrlAbstract/FREE Full Text
    4. ↵
      Goldring SR. Pathogenesis of bone and cartilage destruction in rheumatoid arthritis. Rheumatology2003;42 (suppl 2) :ii11–6.
      OpenUrlAbstract
    5. ↵
      Ritchlin CT, Haas-Smith SA, Li P, et al. Mechanism of TNF-alpha and RANKL mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest2003;11l:821–31.
      OpenUrl
    6. ↵
      Jurisic V , Colovic M. Correlation of sera TNF-alpha with percentage of bone marrow plasma cells, LDH, beta 2 micro globulin, and clinical stage in multiple myeloma. Med Oncol2002;19:133–9.
      OpenUrlCrossRefPubMed
    7. ↵
      Campbell PA, Wang M, Amstutz HC, et al. Positive cytokine production in failed metal on metal total hip replacements. Acta Orthop Scand2002;73:506–12.
      OpenUrlCrossRefPubMed
    8. ↵
      Graves DT, Cochran DN. The contribution of IL-1 and TNF-alpha to periodontal tissue destruction. J Periodont2003;74:391–401.
      OpenUrl
    9. ↵
      Allali F , Breban M, Porcher R, et al. Increase in bone mineral density in patients with spondyloarthropathy treated with anti-TNF-alpha. Ann Rheum Dis2003;62:347–9.
      OpenUrlAbstract/FREE Full Text
    10. ↵
      Geimold AM. New indications for treatment of chronic inflammation by TNF-alpha blockade. Am J Med Sci2003;325:75–92.
      OpenUrlCrossRefPubMedWeb of Science
    11. ↵
      Kast RE, Altschuler EL. Remission of Crohn’s disease on bupropion. Gastroenterology2001;121:1260–1.
      OpenUrlPubMed
    12. ↵
      Kane S , Altschuler EL, Kast RE. Crohn’s disease remission on bupropion. Gastroenterology2003;125:1290.
      OpenUrlCrossRefPubMedWeb of Science
    13. ↵
      Kast RE, Altschuler EL. TNF in hepatitis B: potential role for bupropion. J Hepatol2003;39:131–3.
      OpenUrlPubMed

    Linked Articles